A Multi-center Clinical Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Onatasertib (Primary) ; Carboplatin; Cisplatin; Doxorubicin liposomal; Paclitaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PORCH
- 17 Aug 2021 New trial record